new digs

Aerospace company opens new $30M Houston Spaceport location, plans to move in

Collins Aerospace celebrated the opening of its new facility this week. Image courtesy of Collins Aerospace

Collins Aerospace has cut the ribbon on its new 120,000 square-foot facility located at the Houston Spaceport in Houston — all that's left for the global aerospace and defense company is to move in.

“Collins’ long history of innovating, developing and delivering the critical systems that have played an integral role in humankind’s exploration of space takes yet another step forward with the opening of this state-of-the-art facility at the Houston Spaceport,” says Phil Jasper, president of Collins Aerospace’s Mission Systems business, in a news release.

“This strategic location and our strong local partnerships are driving the next-generation technologies that will enable humankind to live, work and play in space,” he continues.

The new, $30 million facility for Charlotte, North Carolina-based Collins Aerospace, will feature 10,000 square feet dedicated to an incubator supporting aerospace startups.

The unique spaceflight incubator, which was announced to receive up to $25.6 million in financing from Houston Airports for capital improvements, be a place where startups, universities and industry professionals can collaborate using robotics, medicine, additive manufacturing, and more to solve complex space technology challenges.

“The expansion of Collins Aerospace at the Houston Spaceport is a crucial next step in the city’s journey to be the country’s premier next-generation aerospace and technical hub,” says Houston Mayor Sylvester Turner in the release.

“The innovative technologies created at this facility will also serve as the critical systems to support humankind’s future space exploration and habitation. We look forward to fueling the future of aerospace right here in Houston,” he continues.

Collins, which has had a presence in Houston for around 40 years, announced the new facility after reaching capacity at its other location. The expanded operations will add an additional 300 jobs in the coming years.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted